仁济医院及科济药业2020年在Clin Cancer Res发表了临床试验(NCT02395250,NCT03146234)结果,13例病人,根据Kaplan-Meier方法,3年、1年和6个月的总生存率分别为10.5%、42.0%和50.3%。1例病情持续稳定的患者在44.2个月后存活。CAR-T细胞的扩增往往与肿瘤反应呈正相关。
可以检索到10项临床试验,单一治疗的临床试验中显示疗效有限。 NCT02416466,CAR-T Hepatic Artery Infusionsand Sir-Spheres for Liver Metastases (HITM-SIR),RogerWilliams Medical Center. NCT02349724,AClinical Research of CAR T Cells Targeting CEA Positive Cancer,Southwest Hospital, China
1.Victor Moreno et al,Adoptive cell therapy for solid tumors:Chimeric antigen receptor T cells and beyond,CurrentOpinion in Pharmacology 2021, 59:70–842.Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat. Med.24,572–579 (2018).3.Shimizu Y, Suzuki T, YoshikawaT, Endo I and Nakatsura T (2019) Next-Generation Cancer Immunotherapy TargetingGlypican-3. Front. Oncol. 9:248 4. DonghuaShi et al,ChimericAntigen Receptor-Glypican-3 T-Cell Therapy for Advanced HepatocellularCarcinoma: Results of Phase I Trials,Clin Cancer Res .2020 Aug 1;26(15):3979-3989.5. StevenC. Katz et al,HITM-SIR:phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy andselective internal radiation therapy for CEA+ liver metastases,Cancer Gene Therapy https://doi.org/10.1038/s41417-019-0104-z6. ChengchengZhang et al,Phase IEscalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic ColorectalCancers, Molecular Therapy Vol. 25 No 5 May 2017 7. ChristopherC. Kloss et al,Dominant-NegativeTGF-b Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation AndAugments Prostate Cancer Eradication,Molecular TherapyVol. 26 No 7 July 20188. YajunZhang et al,Phase Iclinical trial of EGFR‑specifcCAR‑T cells generated by thepiggyBac transposon system in advanced relapsed/refractory non‑small cell lung cancer patients,Journal of Cancer Researchand Clinical Oncology https://doi.org/10.1007/s00432-021-03613-7 9. YangLiu et al,Anti-EGFRchimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma:A phase I clinical trial,Cytotherapy 22 (2020) 573-580